174 related articles for article (PubMed ID: 23994746)
1. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.
Suzuki A; Xiao L; Taketa T; Sudo K; Wadhwa R; Blum MA; Skinner H; Komaki R; Weston B; Lee JH; Bhutani MS; Rice DC; Maru DM; Erasmus J; Swisher SG; Hofstetter WL; Ajani JA
Ann Oncol; 2013 Nov; 24(11):2854-9. PubMed ID: 23994746
[TBL] [Abstract][Full Text] [Related]
2.
Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
[TBL] [Abstract][Full Text] [Related]
3. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.
Javeri H; Xiao L; Rohren E; Komaki R; Hofstetter W; Lee JH; Maru D; Bhutani MS; Swisher SG; Wang X; Ajani JA
Cancer; 2009 Feb; 115(3):624-30. PubMed ID: 19130466
[TBL] [Abstract][Full Text] [Related]
4. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.
Cheedella NK; Suzuki A; Xiao L; Hofstetter WL; Maru DM; Taketa T; Sudo K; Blum MA; Lin SH; Welch J; Lee JH; Bhutani MS; Rice DC; Vaporciyan AA; Swisher SG; Ajani JA
Ann Oncol; 2013 May; 24(5):1262-6. PubMed ID: 23247658
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.
Suzuki A; Xiao L; Hayashi Y; Macapinlac HA; Welsh J; Lin SH; Lee JH; Bhutani MS; Maru DM; Hofstetter WL; Swisher SG; Ajani JA
Cancer; 2011 Nov; 117(21):4823-33. PubMed ID: 21456015
[TBL] [Abstract][Full Text] [Related]
6. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.
Charalampakis N; Xiao L; Elimova E; Wadhwa R; Shiozaki H; Shimodaira Y; Blum MA; Planjery V; Rogers JE; Matamoros A; Sagebiel T; Das P; Lee JH; Bhutani MS; Weston B; Estrella JS; Badgwell BD; Ajani JA
Oncology; 2015; 89(6):305-10. PubMed ID: 26393501
[TBL] [Abstract][Full Text] [Related]
7. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.
Harada K; Wu CC; Wang X; Mizrak Kaya D; Amlashi FG; Iwatsuki M; Blum Murphy MA; Maru DM; Weston B; Lee JH; Rogers JE; Thomas I; Shanbhag N; Bhutani MS; Hofstetter WL; Nguyen QN; Ajani JA
Ann Surg; 2020 Aug; 272(2):311-318. PubMed ID: 32675544
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
[TBL] [Abstract][Full Text] [Related]
9. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
Taketa T; Correa AM; Suzuki A; Blum MA; Chien P; Lee JH; Welsh J; Lin SH; Maru DM; Erasmus JJ; Bhutani MS; Weston B; Rice DC; Vaporciyan AA; Hofstetter WL; Swisher SG; Ajani JA
Oncology; 2012; 83(5):300-4. PubMed ID: 22964903
[TBL] [Abstract][Full Text] [Related]
10. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
[TBL] [Abstract][Full Text] [Related]
11. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders.
Cerfolio RJ; Bryant AS; Talati AA; Eloubeidi MA; Cerfolio RM; Winokur TS
J Thorac Cardiovasc Surg; 2009 Mar; 137(3):605-9. PubMed ID: 19258075
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Rizk NP; Tang L; Adusumilli PS; Bains MS; Akhurst TJ; Ilson D; Goodman K; Rusch VW
J Thorac Oncol; 2009 Jul; 4(7):875-9. PubMed ID: 19487968
[TBL] [Abstract][Full Text] [Related]
13. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.
Shiozaki H; Sudo K; Xiao L; Wadhwa R; Elimova E; Hofstetter WL; Skinner HD; Lee JH; Weston B; Bhutani MS; Blum MA; Maru DM; Ajani JA
Oncology; 2014; 86(5-6):336-9. PubMed ID: 24925190
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma.
Zafar SN; Blum M; Chiang YJ; Ajani JA; Estrella JS; Das P; Minsky BD; Hofstetter WL; Mansfield P; Badgwell BD; Ikoma N
Ann Thorac Surg; 2020 Aug; 110(2):398-405. PubMed ID: 32289300
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
[TBL] [Abstract][Full Text] [Related]
16. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma.
Taketa T; Sudo K; Correa AM; Wadhwa R; Shiozaki H; Elimova E; Campagna MC; Blum MA; Skinner HD; Komaki RU; Lee JH; Bhutani MS; Weston BR; Rice DC; Swisher SG; Maru DM; Hofstetter WL; Ajani JA
J Natl Compr Canc Netw; 2014 Aug; 12(8):1139-44. PubMed ID: 25099446
[TBL] [Abstract][Full Text] [Related]
17. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Ajani JA; Xiao L; Roth JA; Hofstetter WL; Walsh G; Komaki R; Liao Z; Rice DC; Vaporciyan AA; Maru DM; Lee JH; Bhutani MS; Eid A; Yao JC; Phan AP; Halpin A; Suzuki A; Taketa T; Thall PF; Swisher SG
Ann Oncol; 2013 Nov; 24(11):2844-9. PubMed ID: 23975663
[TBL] [Abstract][Full Text] [Related]
18. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
19. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
20. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
